cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
respirasi@journal.unair.ac.id
Editorial Address
Jl. Mayjen Prof. Dr. Moestopo 6-8 Surabaya 60286 Indonesia
Location
Kota surabaya,
Jawa timur
INDONESIA
Jurnal Respirasi (JR)
Published by Universitas Airlangga
ISSN : 24070831     EISSN : 26218372     DOI : -
Core Subject : Health,
Health Professions Medicine & Pharmacology Public Health
Jurnal Respirasi is a National journal in accreditation process managed by Department of Pulmonology & Respiratory Medicine Faculty of Medicine Airlangga University - Dr. Soetomo General Hospital, Surabaya. Publish every January, May, September every year with each of 5 (five) complete texts in Indonesian.
Arjuna Subject : -
Articles 364 Documents
 33   34   35   36   37 
Revisiting Pleural Effusion Classification: Diagnostic Utility of the Serum-Effusion Albumin Gradient Compared with Light’s Criteria Chairunnisya Chairunnisya; Ricke Loesnihari; Andika Pradana
Jurnal Respirasi Vol. 12 No. 3 (2026): September 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.3.2026.221-229

Abstract

Introduction: Pleural effusion is a common clinical condition resulting from various systemic or local diseases. Differentiating transudative from exudative effusions is essential for determining etiology and management. Light’s criteria remain the standard diagnostic method; however, their accuracy may decrease in certain conditions, such as in patients receiving diuretic therapy. The Serum–Effusion Albumin Gradient (SEAG) has been proposed as a simpler parameter with potential diagnostic value Objective: To evaluate the diagnostic performance of SEAG in differentiating transudative and exudative pleural effusions using Light’s criteria as the reference standard Methods: This cross-sectional analytic study was conducted at Adam Malik Hospital, Medan, from October to December 2025. Sixty-three patients with pleural effusion undergoing thoracentesis were enrolled consecutively. Statistical analyses included the Mann–Whitney test, Chi-square test, Cohen’s Kappa for agreement, and Receiver Operating Characteristic (ROC) curve analysis to determine the optimal cut-off, sensitivity, and specificity of SEAG Results: Based on Light’s criteria, 58.7% of effusions were classified as exudates and 41.3% as transudates. SEAG classified 60.3% as transudates and 39.7% as exudates. A significant association was found between SEAG and Light’s criteria (χ² = 23.753; p < 0.001) with moderate agreement (κ = 0.571; p < 0.001). ROC analysis showed an AUC of 0.813 (95% CI: 0.704–0.923). The optimal SEAG cut-off was 1.295 g/dL, with 92.3% sensitivity and 73% specificity Conclusion: SEAG demonstrated good diagnostic performance and may serve as an additional parameter in differentiating pleural effusions Keywords: Pleural effusion, SEAG, Light’s criteria, transudate, exudate, quality of care
Diagnostic Performance between IDAI and WHO Scoring Systems for Pediatric Tuberculosis Marcelina Pepita Kristiono; Khairiyadi Khairiyadi; Eko Suhartono; Indra Widjaja Himawan; Dyah Roselina
Jurnal Respirasi Vol. 12 No. 3 (2026): September 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.3.2026.230-239

Abstract

Introduction : Tuberculosis (TB) detection in children is challenging, particularly because of their paucibacillary nature. Healthcare facilities may also lack the necessary resources to diagnose this disease properly. Treatment-decision algorithm can be considered as a solution, but their performance need to be evaluated. Objective : To evaluate and compare the diagnostic performance of the IDAI scoring system and the WHO scoring algorithms (A and B) in diagnosing childhood tuberculosis, using bacteriological and/or histopathological examinations as the reference standard. Methods : A quantitative diagnostic study comparing TB scoring results with diagnostic reference. Performance was evaluated based on AUC value from the ROC curve, and agreement between screening methods was evaluated based on Intraclass Correlation Coefficient. Two independent researcher evaluated TB diagnosis in 65 children based on WHO treatment-decision algorithm (A and B version) and IDAI scoring system. Results of AFB, MRT (Xpert MTB/RIF) or FNAB evaluation was used as diagnostic reference. Results : IDAI scoring method has low agreement with both WHO algorithm (κ = 0.228 vs WHO A and 0.265 vs WHO B), with better agreement between the two WHO algorithms (κ = 0.516). The IDAI scoring system has 24.32% sensitivity, 78.57% specificity and diagnostic odds ratio (DOR) >1. Both WHO algorithm have 52.5-54.05% sensitivity, 32.14-36% specificity, and DOR <1. All screening methods showed weak diagnostic performance with AUC between 0.5–0.6 when compared with diagnostic reference, with no significant difference between methods. Conclusion : IDAI scoring system and both WHO algorithms had weak diagnostic performance for TB diagnosis in children
Aspergillus-Specific IgG and Spirometric Changes after Itraconazole in Post-Tuberculosis Patients with Probable Chronic Pulmonary Aspergillosis Uray Riki Arif Maulana; Suryanti Dwi Pratiwi; Rezki Tantular; Nanik Setijowati
Jurnal Respirasi Vol. 12 No. 3 (2026): September 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.3.2026.240-249

Abstract

Introduction: Chronic pulmonary aspergillosis (CPA) is a clinically important complication in patients with post-tuberculosis structural lung disease. Aspergillus-specific immunoglobulin G and spirometric parameters may help assess disease burden and treatment-associated change, but local data from Indonesia remain limited. This study evaluated changes in Aspergillus-specific IgG levels and lung function after itraconazole therapy in post-tuberculosis patients with probable CPA. Methods: This one-group pre-post study was conducted at the Pulmonology Outpatient Department of Dr. Saiful Anwar General Hospital, Malang, Indonesia, from July to December 2024. Post-tuberculosis patients were screened for probable CPA, and 16 patients who fulfilled the study criteria received oral itraconazole 200 mg twice daily for three months. Aspergillus-specific IgG was measured before and after therapy, and spirometric parameters including forced vital capacity, forced expiratory volume in one second, and FEV1/FVC were recorded. Aspergillus-specific IgG was analyzed using the Wilcoxon signed-rank test, while spirometric variables were analyzed using the paired t-test. Results: Twenty-nine post-tuberculosis patients were screened, and 16 fulfilled the criteria for probable CPA and completed the pre-post analysis. Aspergillus-specific IgG decreased from 1.01 ± 1.04 to 0.81 ± 0.94, but the change was not statistically significant (p=0.679). FEV1 increased significantly from 1.14 ± 0.51 L to 1.36 ± 0.69 L (p=0.04). Forced vital capacity increased from 1.95 ± 0.72 L to 2.10 ± 0.76 L (p=0.16), and FEV1/FVC increased from 59.78 ± 18.15 to 63.52 ± 16.23 (p=0.18), although both changes were not statistically significant. Conclusion: In post-tuberculosis patients with probable CPA, three months of itraconazole therapy was associated with a significant increase in FEV1, whereas Aspergillus-specific IgG, forced vital capacity, and FEV1/FVC did not change significantly. Larger controlled studies with longer follow-up are needed to clarify serological and functional response patterns.
Platinum-Based Chemotherapy Regimens and the Incidence of Chemotherapy Toxicity in Patients with Lung Cancer in Medan, Indonesia Faidul Hidayati Siska Ginting; Noni Novisari Soeroso; Setia Putra Tarigan; Putri Chairani Eyanoer; David Chi Leung Lam
Jurnal Respirasi Vol. 12 No. 3 (2026): September 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.3.2026.250-257

Abstract

Introduction: Platinum-based chemotherapy remains the standard first-line therapy for advanced lung cancer; however, its administration is frequently associated with various hematologic and non-hematologic toxicities that may affect patient outcomes and quality of life. Understanding the toxicity profile of platinum-based regimens is essential for optimizing supportive care and treatment monitoring. Objective: This study aimed to analyze the association between platinum-based chemotherapy regimens and the incidence of chemotherapy-related toxicities in lung cancer patients in Medan. Methods: A retrospective study was conducted using medical records of lung cancer patients treated at Prof. dr. Chairuddin P. Lubis Universitas Sumatera Utara Hospital and Adam Malik Hospital from January 2023 to June 2025. Sequential sampling was applied to patients who had received at least two cycles of platinum-based chemotherapy. Hematologic and non-hematologic toxicities were assessed and graded according to the highest toxicity level observed during treatment. Data were analyzed using univariate analysis and Chi-square tests with SPSS version 29. Results: A total of 134 patients were included, predominantly male (85.07%) and aged over 60 years (48.51%). Adenocarcinoma was the most common subtype (57.46%), while carboplatin-based regimens were more frequently administered (75.37%). The most common hematologic toxicity was anemia (76.12%), whereas myalgia (95.52%), pulmonary complications (87.31%), nausea/vomiting (85.82%), and alopecia (75.37%) were the most frequent non-hematologic toxicities. Significant associations were identified between platinum-based chemotherapy regimens and the occurrence of diarrhea (p=0.011) and oral mucositis (p=0.008). Conclusion: Platinum-based chemotherapy in lung cancer patients is associated with substantial hematologic and non-hematologic toxicities, particularly myalgia and pulmonary complications. Carboplatin regimens were more commonly used and generally showed a milder toxicity profile compared with cisplatin. Early monitoring and regimen-specific supportive management are recommended to reduce chemotherapy-related complications.

Page 37 of 37 | Total Record : 364

 33   34   35   36   37 

Filter by Year

2015 2026


Reset
Filter By Issues
All Issue Vol. 12 No. 3 (2026): September 2026 Vol. 12 No. 2 (2026): May 2026 Vol. 12 No. 1 (2026): January 2026 Vol. 11 No. 3 (2025): September 2025 Vol. 11 No. 2 (2025): May 2025 Vol. 11 No. 1 (2025): January 2025 Vol. 10 No. 3 (2024): September 2024 Vol. 10 No. 2 (2024): May 2024 Vol. 10 No. 1 (2024): January 2024 Vol. 9 No. 3 (2023): September 2023 Vol. 9 No. 2 (2023): May 2023 Vol. 9 No. 1 (2023): January 2023 Vol. 8 No. 3 (2022): September 2022 Vol. 8 No. 2 (2022): May 2022 Vol. 8 No. 1 (2022): January 2022 Vol. 7 No. 3 (2021): September 2021 Vol. 7 No. 2 (2021): May 2021 Vol. 7 No. 1 (2021): January 2021 Vol. 6 No. 3 (2020): September 2020 Vol. 6 No. 2 (2020): May 2020 Vol. 6 No. 1 (2020): January 2020 Vol. 5 No. 3 (2019): September 2019 Vol. 5 No. 2 (2019): Mei 2019 Vol. 5 No. 1 (2019): Januari 2019 Vol. 4 No. 3 (2018): September 2018 Vol. 4 No. 2 (2018): Mei 2018 Vol. 4 No. 1 (2018): Januari 2018 Vol. 3 No. 3 (2017): September 2017 Vol. 3 No. 2 (2017): Mei 2017 Vol. 3 No. 1 (2017): Januari 2017 Vol. 2 No. 3 (2016): September 2016 Vol. 2 No. 2 (2016): Mei 2016 Vol. 2 No. 1 (2016): Januari 2016 Vol. 1 No. 3 (2015): September 2015 Vol. 1 No. 2 (2015): Mei 2015 Vol. 1 No. 1 (2015): Januari 2015 More Issue